Borrelia Burgdorferi Strain Ips 930-34-081596; Borrelia Burgdorferi Strain B-31

Verify with FDA CVM →

196 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
196
Total Reports
20
Deaths Reported
1020.0%
Death Rate

Active Ingredients

Borrelia Burgdorferi Strain Ips 930-34-081596; Borrelia Burgdorferi Strain B-31

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 196

Most Affected Breeds

Retriever - Labrador 25
Shih Tzu 12
Terrier - Bull - American Pit 10
Terrier - Yorkshire 10
Retriever - Golden 9
Boxer (German Boxer) 8
Terrier - Jack Russell 7
Crossbred Canine/dog 6
Beagle 6
Chihuahua 6

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 61
Vomiting 57
Anorexia 36
Anaphylactoid reaction 34
Other abnormal test result NOS 25
Facial swelling (see also 'Skin') 22
Diarrhoea 22
Urticaria 19
Emesis 15
Lameness 15
Injection site swelling 14
Fever 14

Outcome Breakdown

Ongoing
107 (54.6%)
Recovered/Normal
60 (30.6%)
Euthanized
13 (6.6%)
Outcome Unknown
9 (4.6%)
Died
7 (3.6%)

Data Summary

Metric Value
Total adverse event reports 196
Reports involving death 20
Case-fatality rate (reported events) 1020.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Borrelia Burgdorferi Strain Ips 930-34-081596; Borrelia Burgdorferi Strain B-31 Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 196 adverse event reports referencing Borrelia Burgdorferi Strain Ips 930-34-081596; Borrelia Burgdorferi Strain B-31, including 20 reports in which the animal died — a 1020.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Borrelia Burgdorferi Strain Ips 930-34-081596; Borrelia Burgdorferi Strain B-31. Reported administration routes include Subcutaneous, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Borrelia Burgdorferi Strain Ips 930-34-081596; Borrelia Burgdorferi Strain B-31 reports are Dog (196 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (25), Shih Tzu (12), Terrier - Bull - American Pit (10) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Borrelia Burgdorferi Strain Ips 930-34-081596; Borrelia Burgdorferi Strain B-31 are Lethargy (see also Central nervous system depression in 'Neurological') (61), Vomiting (57), Anorexia (36), Anaphylactoid reaction (34). Of the 196 reports with a coded outcome, Ongoing is the leading category at 54.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Borrelia Burgdorferi Strain Ips 930-34-081596; Borrelia Burgdorferi Strain B-31.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial